Zobrazeno 1 - 10
of 652
pro vyhledávání: ''
Autor:
Hailing Cheng, Pixu Liu, Li Li, Zhiwei Tao, Zundong Liu, Yichao Liu, Xiaolin Sang, Chunhua Rui
Publikováno v:
Cancer Letters. 518:82-93
Despite HER2-targeted cancer treatments have provided considerable clinical benefits, resistance to HER2-targeted agents will inevitably develop. Targeting non-oncogene vulnerabilities including endoplasmic reticulum (EnR) stress has emerged as an at
Autor:
Philip He, Robin Kate Kelley, Ho Yeong Lim, Takuji Okusaka, Thomas Yau, David Wai-Meng Tai, Ghassan K. Abou-Alfa, Masafumi Ikeda, Bruno Sangro, Yoon-Koo Kang, Silvia Damian, Johanna C. Bendell, Mitesh J. Borad, William P. Harris, Tae-You Kim, Shukui Qin, Alejandra Negro, Mallory Makowsky, Nathan Standifer, Masatoshi Kudo, Ann-Lii Cheng, Jordi Bruix, Antonio Gasbarrini, Wei Peng Yong
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 39, iss 27
PURPOSE This phase I/II study evaluated tremelimumab (anticytotoxic T-lymphocyte–associated antigen-4 monoclonal antibody) and durvalumab (antiprogrammed death ligand-1 monoclonal antibody) as monotherapies and in combination for patients with unre
Publikováno v:
Trends Cancer
Biguanides are a class of anti-diabetic drugs that includes phenformin and metformin, however, the former was withdrawn from approval in many countries due to its toxicity. Findings from retrospective epidemiological studies in diabetic populations a
Publikováno v:
Clinical & Translational Oncology
Purpose Proper monitoring and management of chemotherapy-induced nausea and vomiting (CINV) with antiemetics is crucial for cancer patients. This study aimed to evaluate the use of antiemetics for the treatment of highly emetogenic chemotherapy (HEC)
Autor:
Huamao M. Lin, D. Ross Camidge, Maurice Pérol, Mohammad Jahanzeb, Yanyan Zhu, Pingkuan Zhang, Sanjay Popat, Maria Rosario Garcia Campelo
Publikováno v:
Lung Cancer. 155:68-77
In ALTA-1 L, first-line brigatinib versus crizotinib significantly prolonged progression-free survival in advanced ALK-positive (ALK+) non-small cell lung cancer (NSCLC). We report health-related quality of life (HRQOL) outcomes from ALTA-1 L.HRQOL w
Autor:
Hope S. Rugo, Stephen Chia, Wei-Chun Hsu, Juan Pablo Zarate, Hemanth Kanakamedala, David Chandiwana, Chu-Ling Yu, Jinhee Park, Antonia Ridolfi, Stuart J. Turner
Publikováno v:
The Oncologist
Background The BYLieve trial (NCT03056755) confirmed efficacy and safety of alpelisib with fulvestrant for hormone receptor–positive (HR+), human epidermal growth factor receptor‐2–negative (HER2−), PIK3CA‐mutated advanced breast cancer (AB
Autor:
Stuart J. Turner, Stephen Chia, Nicholas C. Turner, Wei-Chun Hsu, Yeon Hee Park, Patrick Neven, Florence Lerebours, Pamela Drullinsky, Christina Arce, Manuel Ruiz-Borrego, Yu-Ming Shen, Eva Ciruelos, Juan Pablo Zarate, Hope S. Rugo, Nickolas Sophos, Dejan Juric, Aleix Prat, Thomas Bachelot, Hemanth Kanakamedala
Publikováno v:
The Lancet Oncology. 22:489-498
Summary Background Alpelisib, a PI3Kα-selective inhibitor and degrader, plus fulvestrant showed efficacy in hormone receptor-positive, HER2-negative, PIK3CA-mutated advanced breast cancer in SOLAR-1; limited data are available in the post-cyclin-dep
Autor:
Takao Shimazoe, Mayako Uchida, Daisuke Kobayashi, Natsumi Yamanaka, Mizuki Inoue, Takehiro Kawashiri, Shiori Hiromoto, Keisuke Mine
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-6 (2021)
Scientific Reports
Scientific Reports
Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a major side effect of capecitabine. Although the pathogenesis of HFS remains unknown, some studies suggested a potential involvement of inflammation in its pathogene
Publikováno v:
Cancer Investigation. 39:235-239
Comprehensive molecular testing of individual tumors has led to the identification of novel molecularly defined cancer therapies and treatment indications. Given low frequencies of many molecular alterations, efficacy of therapies used to target them
Autor:
Alexander Melamed, Melissa Beauchemin, Melissa K. Accordino, Jason D. Wright, Dawn L. Hershman, Jacob C Cogan, Rohit R. Raghunathan
Publikováno v:
Cancer Research. 81:GS3-08
Introduction Cancer surgery has been linked to chronic opioid use post-operatively, with up to 10% of patients continuing to fill opioid prescriptions beyond 3 months after surgery. However, previous studies have not compared post-operative opioid us